Form 4: Skye Bioscience Director Sells Over 230K Shares

Andrew J. Schwab, a Director and 10% owner of Skye Bioscience, Inc., reported the sale of 231,405 shares of common stock in August 2025.

Summary

• Andrew J. Schwab, a Director and 10% owner of Skye Bioscience, Inc. (SKYE), reported the sale of common stock through affiliated investment entities.
• On August 21, 2025, 5AM Ventures II, L.P. sold 58,642 shares of common stock at a weighted average price of $3.57 per share (ranging from $3.55 to $3.69).
• On August 21, 2025, 5AM Co-Investors II, L.P. sold 2,314 shares of common stock at a weighted average price of $3.57 per share (ranging from $3.55 to $3.69).
• On August 22, 2025, 5AM Ventures II, L.P. sold 163,979 shares of common stock at a weighted average price of $3.42 per share (ranging from $3.30 to $3.59).
• On August 22, 2025, 5AM Co-Investors II, L.P. sold 6,470 shares of common stock at a weighted average price of $3.42 per share (ranging from $3.30 to $3.59).
• The total number of shares sold across these transactions is 231,405.
• These transactions were conducted pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, 5AM Ventures II, L.P. beneficially owns 1,457,064 shares, 5AM Co-Investors II, L.P. beneficially owns 57,493 shares, and 5AM Ventures VII, L.P. beneficially owns 8,167,206 shares.
• Mr. Schwab, as a managing member of the general partners of these entities, disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The filing reports significant sales of common stock by a Director and 10% owner. While these sales were conducted under a Rule 10b5-1 plan, which suggests pre-planning rather than opportunistic selling, large insider sales can still be perceived negatively by the market. The indirect nature of ownership and the disclaimer of full beneficial ownership by Mr. Schwab also factor into a slightly less negative sentiment than direct, personal, open-market sales.

Positives

• The reported transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled sales rather than opportunistic selling based on immediate, non-public information.

Negatives

• A Director and 10% owner, Andrew J. Schwab, reported significant sales of common stock totaling 231,405 shares.
• The sales occurred at weighted average prices of $3.57 and $3.42, which could be perceived as a lack of confidence in higher future prices, although the 10b5-1 plan mitigates this interpretation somewhat.

Risks

• Investor perception risk: Significant insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence by insiders, potentially leading to negative sentiment or downward pressure on the stock price.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially impacting stock price due to perceived lack of confidence by an insider.

Key Dates

Recommendation

While significant insider selling by a director and 10% owner could typically warrant a 'sell' recommendation, the fact that these transactions were executed under a Rule 10b5-1 plan mitigates the immediate negative signal. A 10b5-1 plan indicates the sales were pre-scheduled and not based on recent, non-public information. Therefore, a 'hold' recommendation is more appropriate, advising investors to monitor future developments and broader company performance rather than reacting solely to these pre-planned sales.

Keywords

Skye Bioscience, SKYE, Form 4, Insider Trading, Stock Sale, Director, 10% Owner, Andrew J. Schwab, 5AM Ventures, Beneficial Ownership, SEC Filing, Rule 10b5-1